Compare BridgeBio Pharma Inc (BBIO) vs Harmony Gold Mining Co. (HMY) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Harmony Gold Mining (HMY) trades at $19.90, up 0.96% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with 2024 revenue of $61.38B and net income of $8.59B, achieving a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but strong operational cash flow growth to $15.65B in 2024. The stock's valuation remains reasonable with P/E of 12.26 and EV/EBITDA of 6.41, while the company transitions toward gold-copper diversification.

HMY presents a compelling value proposition with attractive profitability metrics and strategic diversification, though analyst sentiment remains cautious with 70% hold ratings. Key risks include gold price volatility and execution challenges in copper expansion. The stock trades near resistance at $20-21 with overbought RSI signals suggesting potential near-term consolidation before further upside.